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Abstract
Pomegranate (Punica granatum), a polyphenol-rich fruit, has been suggested to reduce cardiovascular risk due to its antioxidant properties. Hypertension and
obesity are the most preventable cardiovascular risk factors. Few studies on blood pressure and/or body-weight status have been conducted in human
subjects. Previous investigations have tended to focus on pomegranate juice. The aim of the present study was to investigate the effect of pomegranate
extract (PE) on blood pressure and anthropometric measures in adults with no symptomatic disease. A total of ﬁfty-ﬁve participants enrolled in a rando-
mised double-blinded placebo-controlled clinical trial where they were assigned to either PE capsules or placebo capsules for 8 weeks. Blood pressure, body
weight, waist circumference, waist:hip ratio (WHR) and body composition (lean body mass, body fat) were measured at baseline, week 4 and week
8. Results showed a signiﬁcant decrease in diastolic blood pressure after 8 weeks (by 2·79 (SD 5·32) mmHg; P< 0·05), while the decrease in systolic
blood pressure did not reach statistical signiﬁcance (2·57 (SD 7·4) mmHg; P > 0·05). Body fat percentage, lean body mass, waist circumference and
WHR did not signiﬁcantly differ between groups at the end of the intervention. Results suggest that PE may reduce blood pressure and possibly prevent
hypertension in the normotensive population. Further large trials are required to elucidate this effect.
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CVD currently affects more than 7 million individuals in the
UK and is responsible for 26 % of total deaths(1). High
blood pressure is the greatest contributor to CVD worldwide
and one of the most common CVD risk factors(2). Obesity
remains a global epidemic and is an independent risk factor
for CVD. It is also associated with increased blood pressure,
morbidity and mortality risks, and decreased life expectancy(3).
The beneﬁts of lowering blood pressure and reducing obesity
for the prevention of CVD are well established. Studies have
reported that a reduction in systolic blood pressure (SBP)
and/or diastolic blood pressure (DBP) by 5 mmHg is clinically
signiﬁcant as it decreased cardiovascular risk by 20 %(4), the
risk of stroke by 20 %(5) and mortality risk by 7 %(6).
Moreover, a modest weight loss (5–10 %) can signiﬁcantly
decrease risk factors for diabetes and CVD(7,8). Therefore,
attenuating obesity and blood pressure could have a potential
effect on reducing CVD risk in the population.
In addition to diet and exercise, the study of complementary
approaches for the prevention and management of CVD is
now emerging. Bioactive components, particularly polyphe-
nols, have been studied for their potential beneﬁcial effects
on health. Pomegranate has a high antioxidant capacity due
its considerable polyphenol content, particularly tannins,
anthocyanins and ellagic acid derivatives(9). Pomegranate has
been reported to reduce inﬂammation(10), lipid peroxidation,
oxidative stress(11) and insulin resistance(12). Some studies
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have shown that pomegranate juice reduces blood pressure in
hypertensive(13) and normotensive populations(14,15). However,
another study showed that 3 months of pomegranate juice sup-
plementation did not signiﬁcantly affect blood pressure in
patients with CHD(16). In addition, Mathew et al.(17) showed
that pomegranate extract (PE) suppressed the postprandial
increase in SBP following a high-fat meal(17). A randomised con-
trolled parallel trial including twenty-nine participants also illu-
strated that 4 weeks of daily PE supplementation reduced SBP
(from 120·3 (SD 13·3) to 115·6 (SD 13·1) mmHg; P= 0·012),
while no signiﬁcant changes occurred in the control group(18).
In relation to obesity, PE has been reported to decrease body-
weight gain in animals who were administered a high-fat
diet(18–22). However, its effects in humans remain unclear. One
study reported that pomegranate juice supplementation for 1
month prevented weight gain and body fat increase in obese
humans (P< 0·05), while the latter parameters signiﬁcantly
increased in the control group administered juice with
no polyphenols (P< 0·05)(23). This research aimed to study the
potential preventive effect of pomegranate on cardiovascular
risk by exploring the effect of PE on SBP (primary outcome),
DBP and body-weight status in an adult normotensive
population.
Experimental methods
This trial was registered in clinicaltrials.gov as NCT02017132
(https://clinicaltrials.gov/ct2/show/NCT02017132).
Participants
Participants were recruited from the local community between
April 2013 and December 2013 through advertising in the
Queen Margaret University (QMU) research recruitment digest
and by word of mouth. Eligible participants included men
and women, aged 18–65 years with a BMI between 18 and
34·9 kg/m2. Volunteers answered the pre-assessment question-
naire before they registered for the study to ensure that they did
not have any symptomatic disease. Exclusion criteria included
taking medication for diabetes, heart, liver or kidney disease;
weight loss within 2 months preceding the study; pregnancy;
lactation; and allergies to pomegranate. Participants with a regu-
lar intake of pomegranate were also excluded.
Ethics
The study was granted ethical approval by the Divisional
Ethics Committee at QMU. The intervention was conducted
according to the guidelines laid down in the Declaration of
Helsinki(24). Information sheets were provided to all potential
volunteers and written informed consent was obtained prior to
participation. All collected data were stored according to the
Data Protection Act (1998)(25).
Study design and protocol
The study had a double-blinded parallel controlled design
where participants were randomised to the daily intake of
either one PE capsule or placebo capsule for 8 weeks. Each
participant attended the QMU laboratory on three visits (base-
line, week 4 and week 8), during which clinical and anthropo-
metric measurements were taken. The randomisation process
was conducted by technical staff independent of the study
who allocated treatment using an Internet random number-
generator site(26). The numbers produced were used to allocate
the pomegranate and placebo capsules, which looked identical.
These were placed in sealed, labelled and pre-prepared opaque
containers. Participants were asked to maintain their usual diet
and exercise regimens throughout the intervention.
For each visit, participants were asked to visit the QMU
laboratory during a fasting state (after 8 h of food and
drink restriction). For consistency, participants were asked
to consume one PE or placebo capsule daily after a meal
(the same chosen meal each day) with a glass of water.
Weight, height, waist circumference, hip circumference,
body composition (body fat and lean body mass) and blood
pressure measurements were collected at baseline, week 4
and week 8. BMI and waist:hip ratio were then calculated.
Total antioxidant capacity, total polyphenols levels and
levels of malonaldehyde were measured as biomarkers of
compliance through 24-h urine collections at baseline and
week 8. Post-intervention measurements were recorded inde-
pendently on different sheets, without reference to the initial
set of measurements.
Pomegranate extracts for intervention
All pomegranate capsules and placebo capsules were supplied
and produced by ProbelteBio in Spain from specially culti-
vated pomegranates grown on their horticultural farms.
Capsules contained a 100 % natural concentrated extract of
the whole pomegranate (Pomanox®) obtained through a
water-based, eco-friendly extraction process. They are standar-
dised for punicalagins. Individual PE capsules comprised: 210
mg of punicalagins, 328 mg of other pomegranate polyphenols
(such as ﬂavonoids and ellagic acid) and 0·37 mg of anthocya-
nins, while placebo capsules consisted of maltodextrin. Both
capsules provided a negligible amount of energy (6·52 kcal
(27·28 kJ) per capsule). The polyphenol composition of both
PE and placebo capsules was validated against the company’s
data at the James Hutton Institute, Dundee. The LC-MS
results conﬁrmed that placebo capsules effectively contained
no polyphenols and that the PE capsules contained punicala-
gins (Fig. 1) at the expected ratio compared with the other poly-
phenol components (Supplementary material, Supplementary
Table S1).
Blood pressure
Based on the Centers for Disease Control and Prevention
(CDC) recommendations, blood pressure was measured by a
digital sphygmomanometer (Omron MS-1), with the partici-
pants in a seated position, using the right arm, following a
10-min rest. The arm was positioned so that the midpoint
of the upper arm was at the same level as the heart, and the
























































































































artery. Blood pressure was measured three times on each occa-
sion and the average was calculated.
Anthropometric measures
Anthropometric measurements were conducted following
the National Health and Nutrition Examination Survey
(NHANES) handbook protocols and methods(27). Weight
was measured in the same clothing, with no shoes, on Salter
scales (9018S SV3R). Height was measured on a SECA
Leicester stadiometer (no. 5) with a sensitivity of 1 mm.
Waist and hip circumferences were measured by a Lufkin
W606PM Thinline Executive diameter steel tape yellow clad
(6 mm× 2 m; Cooper Tools). Body composition was mea-
sured through bioelectrical impedance analysis (BIA) using
the Bodystat 1500 (2002) machine. BIA measurements were
conducted after the participant had rested in a supine position
for approximately 10 min. Participants were fasted and advised
to void their bladders before the session.
Urine collection
A 24-h urine sample collection was required the day before
both the baseline and week 8 visits. Total urine was weighed,
sampled into 15 ml tubes, then aliquoted for use. Aliquots
were frozen at −25°C before testing. Total polyphenols
were analysed by the Folin and Ciocalteau method, and the
total antioxidant capacity was determined through the ferric-
reducing antioxidant power (FRAP) assay. The measurement
of malonaldehyde levels (indicator of lipid peroxidation) was
performed through the thiobarbituric acid-reactive substances
method as previously described(28).
Diet diaries
To account for any changes in energy and macronutrient
intake (carbohydrate, protein, fat) which could inﬂuence the
results, a 3 d food diary was collected at baseline and over
the same days of the week during week 4. Nutrient intakes
were generated using Netwisp Software V4.0 (Tinuviel
Software). Food recording support and training, including
guidance on portions sizes and household measures, were pro-
vided by the researcher to assist participants in completing the
food diaries.
Sample size and statistical analysis
Based on 80 % power, a sample size of ﬁfty-two participants
was required to achieve a difference of 5·6 mmHg in SBP
between the PE and placebo groups assuming that the
Fig. 1. Phenolic content in both placebo and pomegranate capsules. Phenolic components in pomegranate study capsules. UV traces are at 280 nm; placebo and
study capsules were extracted as per methods (see Supplementary material). Peaks 3 and 6 are the punicalagin peaks. Full-scale deflection compared at 1·5 × 106
























































































































common standard deviation is 7 mmHg using a two-group t
test with a 0·05 two-sided signiﬁcance level. These assump-
tions were derived from an exploratory study previously con-
ducted at QMU on PE and blood pressure(18). Assuming 5 %
attrition, ﬁfty-ﬁve participants were recruited.
Data were analysed using SPSS for Windows version 21.0
(SPSS) and expressed as means and standard deviations. For
multiple comparisons, data were analysed using two-way
mixed-model ANOVA with time (baseline, week 4, and
week 8) as the within-subject factor, and treatment (PE/pla-
cebo) as the between-subject factor. FRAP and total polyphe-
nols in the urine were analysed using ANCOVA. Energy,
protein, fat and carbohydrate intakes were analysed using
paired t tests. Signiﬁcance was set at P≤ 0·05.
Results
Of the ﬁfty-ﬁve participants in the trial, ﬁfty-three completed
the study. There were twenty-two females in the PE group and
eighteen in the placebo group. The participant ﬂow diagram is
shown in Fig. 2. One participant dropped out before the
second appointment and another participant dropped out
before the third appointment. Participants with at least two
valid time points were included in the analysis. All participants
adhered to the protocol. Baseline characteristics of the studied
population are shown in Table 1.
Changes in blood pressure
ANOVA showed no signiﬁcant interaction between treatment
and time for SBP (F2,102 = 1·2; P= 0·30). However, the
interaction was signiﬁcant for DBP (F2,102 = 4·4; P = 0·02).
In the PE group, DBP decreased by 2·79 (SD 5·32) mmHg
after 8 weeks, while the decrease in SBP (by 2·57 (SD 7·4)
mmHg) did not reach statistical signiﬁcance (Fig. 3).
Anthropometric measures
Results showed no statistically signiﬁcant interaction between
the intervention and time for body weight (F1·6,81·7 = 0·24;
P= 0·74), BMI (F1·7,86·9 = 0·57; P = 0·54), waist circumfer-
ence (F2,106 = 0·25; P = 0·78), waist:hip ratio (F1·6,86·6 = 1·08;
P= 0·34), body fat percentage (F1·5,76·5 = 2·02; P = 0·15) and
lean body mass percentage (F1·2,60·3 = 0·05; P = 0·87). In add-
ition, there was no signiﬁcant difference between the two
groups for all the measures (P > 0·05). Data are presented in
Table 2.
Fig. 2. Participant flow diagram.
Table 1. Baseline characteristics of the intention-to-treat dataset
(Mean values and standard deviations)
PE group (n 28) Placebo group (n 27)
Mean SD Mean SD
Age (years) 30·14 10·95 34·11 11·28
Weight (kg) 70·34 11·3 68·85 12·00
BMI (kg/m2) 24·76 3·83 23·57 3·44
WC (cm) 77·25 8·76 76·01 11·02
WHR 0·76 0·54 0·77 0·80
Body fat (%) 27·56 8·56 24·07 7·22
LBM (%) 72·11 8·45 74·78 8·91
SBP (mmHg) 116·46 9·94 116·81 11·81
DBP (mmHg) 71·54 8·57 70·37 7·96
PE, pomegranate extract; WC, waist circumference; WHR, waist:hip ratio; LBM, lean
























































































































Total polyphenols and total antioxidant capacity and
malonaldehyde levels
After adjustment for pre-intervention levels of all biomarkers,
there was no statistically signiﬁcant difference in post-
intervention levels in both groups for total antioxidant capacity
(F1,47 = 0·19; P = 0·7), total polyphenol levels (F1,48 = 0·98;
P= 0·98) and levels of malonaldehyde (F1,47 = 0·11; P= 0·74)
in the urine (Table 3).
Diet diaries
Analysis showed no signiﬁcant differences in baseline levels of
energy (P = 0·08), carbohydrate (P = 0·4), protein (P = 0·23)
and fat (P = 0·06) levels between the PE group and the pla-
cebo group. Also, analysis via paired t tests showed no
signiﬁcant differences in the energy and macronutrient intake
between baseline and week 4 in both groups (Table 4).
Discussion
This study investigated the effect of 8 weeks of PE supple-
mentation on blood pressure and anthropometric measures
in volunteers with no symptomatic disease. Results indicate
that PE induced a signiﬁcant decrease in DBP (by 2·8 (SD
5·32) mmHg) in the PE group and therefore can offer a pro-
tection against CVD. Although SBP decreased in the PE
group (by 2·57 (SD 7·4) mmHg) compared with the placebo
group (by 0·12 (SD 6·02) mmHg) at the end of the interven-
tion, the difference between the groups did not reach statistical
signiﬁcance. The decrease in blood pressure is in line with our
Fig. 3. Changes in systolic blood pressure (SBP) (a) and diastolic blood pressure (DBP) (b) between groups at different time points. Results are means, with stand-
ard errors represented by vertical bars. * There was a significant interaction between treatment and time for DBP (F2,102 = 4·4; P = 0·02) but not for SBP (F2,102 = 1·2;
P = 0·30). DBP decreased by 2·79 (SD 5·32) mmHg after 8 weeks in the pomegranate extract group (-♦-) while the decrease in SBP (by 2·57 (SD 7·4) mmHg) did not
reach statistical significance. , Placebo group.
Table 2. Changes in outcomes variables at different time points in the pomegranate extract (PE) and placebo groups*
(Mean differences and standard deviations)
PE group (n 28) Placebo group (n 26)
Difference at week 4
from baseline
Difference at week 8
from baseline
Difference at week 4
from baseline
Difference at week 8
from baseline
Mean SD Mean SD Mean SD Mean SD
Body weight (kg) 0·32 1·1 −0·14 1·43 0·23 1·50 0·3 1·87
BMI (kg/m2) 0·11 0·44 0·01 5·46 0·12 0·50 0·15 6·38
WC (cm) 0·17 0·4 0·14 0·41 0·17 0·45 0·21 0·55
WHR 0·00 0·4 0·00 0·14 −0·03 0·14 −0·45 0·20
Body fat (%) −0·19 2·1 0·45 2·68 0·88 2·40 0·49 2·35
LBM (%) 0·51 3·01 0·68 3·23 0·29 4·36 0·75 4·37
WC, waist circumference; WHR, waist:hip ratio; LBM, lean body mass.
* Data were analysed using ANOVA.
Table 3. Total antioxidant capacity, total polyphenols and malonaldehyde (MDA) levels in the urine*
(Mean values and standard deviations)
PE group Placebo group
Baseline Week 8 Baseline Week 8
Mean SD Mean SD Mean SD Mean SD
TAC (mg GAE/d) 6·86 1·7 6·43 1·86 6·6 1·92 6·49 1·94
Total polyphenols (mg GAE/d) 687·6 239 682 252·6 790 395 676 239
MDA levels (μmol MDA/d) 0·72 0·29 0·75 0·39 0·89 0·39 0·78 0·39
TAC, total antioxidant capacity; GAE, gallic acid equivalents.
























































































































previous exploratory study, yet this earlier investigation noted a
signiﬁcant decrease only in SBP but not DBP(18). The blood
pressure-lowering effect is also consistent with previous stud-
ies carried out on pomegranate juice. In fact, a recent
meta-analysis has established an association between blood
pressure and pomegranate juice consumption(29). Our study
presents therefore a novel aspect as limited research has
assessed the effect of PE on CVD risk factors. Given the con-
cerns about obesity resulting from a positive energy imbal-
ance(30), demonstrating beneﬁcial effects of a low-energy
extract of pomegranate would be useful. It would overcome
the increase in energy intake resulting from consumption of
large quantities of juice.
It is worth mentioning that Seeram et al.(31) reported no sig-
niﬁcant difference in the bioavailability of polyphenols from
pomegranate juice (875 mg of polyphenols) and extracts
(755 mg of polyphenols). This was demonstrated by similar
changes in serum ellagic acid levels following consumption
of both pomegranate products on different days(31). This ﬁnd-
ing provides a justiﬁcation for the comparison between differ-
ent forms of pomegranate. Therefore, it could be suggested
that the consistent results obtained with pomegranate juice
rely in the use of higher doses of polyphenols compared
with our study (PE contained 538 mg of polyphenols). For
instance, the study of Tsang et al.(15) reported a signiﬁcant
decrease in both SBP and DBP following the administration
of pomegranate juice (842·5 mg of polyphenols) daily for 4
weeks(15). This provides a rationale for carrying out studies
investigating different doses of polyphenols in a PE on
blood pressure.
Mechanisms of action of PE on blood pressure may involve
the role of polyphenols in reducing serum angiotensin-
converting enzyme (ACE) activity as shown in the study of
Aviram & Dornﬁeld(13). The latter studied the effect of 2
weeks of pomegranate juice supplementation on blood pres-
sure and showed a 36 % decrement in serum ACE activity
and a 5 % reduction in SBP (P < 0·05). The reduction in
ACE levels could be related to the antioxidant properties of
pomegranate and their beneﬁcial effect on endothelial function
and blood pressure(13). Another potential mechanism involves
the role of polyphenols in increasing nitric oxide levels(32). To
clarify which mechanisms may be responsible for these effects
requires further human studies.
Importantly, although the signiﬁcant decrease in DBP was
statistically signiﬁcant, there is a question about the clinical
relevance of this ﬁnding. A 5 mmHg decrease in DBP was
considered to be clinically signiﬁcant(33). Therefore, results
might not be clinically signiﬁcant for all participants. This
might be explained by the fact that our population was normo-
tensive. For instance, SBP decreased by 5 % in hypertensive
participants administered pomegranate juice(13). Further
research is needed to study the clinical effect of pomegranate
and bioactive components on blood pressure and demonstrate
whether their preventive effects on hypertension can be rele-
vant only in conjunction with other lifestyle medications
such as diet and physical activity.
The decrease in DBP was not associated with a signiﬁcant
increase in total polyphenols, total antioxidant capacity or a
decrease in malonaldehyde levels in the urine in the PE
group compared with the placebo group. Apart from possible
non-compliance with the intervention (or the urine collection
itself), these outcomes could also be attributed to the intra-
and inter-individual variability in the metabolism of polyphe-
nols(34). Furthermore, despite the importance of determining
compliance to polyphenol intervention, the short half-life of
polyphenols (1–5 d) can present a potential limitation, even
with repeated daily intakes(35). Therefore, the biomarker of
compliance testing in studies with duration of more than 5 d
may be affected. There were also marked differences in the
volume of the collected 24-h urine between the pre- and post-
samples for thirteen participants, indicating a potential
decrease in compliance in providing the 24-h samples.
The analysis of body weight, waist circumference and waist:
hip ratio did not report signiﬁcant interaction between time
and treatment on the effects. Body composition measurement
was undertaken to explain any potential change in body
weight, waist circumference and waist:hip ratio resulting
from the intervention. This ﬁnding is not in line with several
animal studies which demonstrated a signiﬁcant lowering
effect of pomegranate on body weight(19–22); however, these
studies administered PE in the context of a high-fat diet. It
has previously been hypothesised that polyphenols might
have a counteracting effect on the increase in body weight
caused by an increased energy intake(36). This has been sug-
gested to be mediated by suppressing food intake and inhibit-
ing pancreatic activity(18). The differing results in this study
could be due to the inclusion of normal-weight participants
and overweight participants following their usual diet. These
ﬁndings may then provide a direction for future research in
studying the effects of pomegranate in the obese population.
Comparing the effect of pomegranate in the context of a nor-
moenergetic and a high-energy diet or high-fat diet would con-
tribute towards testing the hypothesis generated by animal
studies.
The study poses both potential strengths and limitations.
Three biomarkers were used to assess participant compliance.
In addition, the study was randomised and double-blinded
which avoided expectation and selection bias. However, the
Table 4. Energy and macronutrient intakes at baseline and week 4 in the
pomegranate extract (PE) and placebo groups
(Mean values and standard deviations)
Intervention
Run-in period Week 4
n Mean SD Mean SD
Energy
kJ PE 28 8661 1929 8644 3125
Placebo 26 9452 1766 9242 2096
kcal PE 28 2070 461 2066 747
Placebo 26 2259 422 2209 501
Carbohydrate (g) PE 28 264 98 264 134
Placebo 26 281 69 280 92
Protein (g) PE 28 79 19 78 21
Placebo 26 85 20 80 19
Fat (g) PE 28 79 28 82 35
Placebo 26 90 22 87 21
























































































































sample size did not provide enough power to explore the
effect of other factors such as age and weight status and
women represented the majority of the population, which
might affect generalisation of results. The ﬁndings are also lim-
ited by the lack of knowledge of the physiological mechanisms
underlying the decrease in DBP.
Conclusion
This study showed that a PE signiﬁcantly lowered DBP over 8
weeks and could contribute to the prevention of CVD risk fac-
tors. However, its effect on SBP and body-weight status was
not signiﬁcant. Further long-term studies with a larger popu-
lation and using different doses of polyphenols are required
to corroborate these effects and to provide direction for future
recommendations.
Supplementary material
The supplementary material for this article can be found at
https://doi.org/10.1017/jns.2017.36
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